Logo

Boehringer Ingelheim Reports Results of BI 695502 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC

Share this

Boehringer Ingelheim Reports Results of BI 695502 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC

Shots:

  • The P-III trial evaluates the safety, efficacy, immunogenicity, and PK of BI 695502 vs bevacizumab RP (Avastin) in patients with recurrent or metastatic NSCLC
  • The results showed an ORR (54% vs 63.1%) @18wks. & showed 90% CI for the primary efficacy, patients had ECOG PS of 1 (63.0% vs 60.4%) & more patients had brain lesions (6.6% vs 3.7%), m-PFS (8.3mos. vs 9.0mos.), m-OS (15.6mos. vs 19.5), Plasma concentrations were higher in the bevacizumab RP group
  • Additionally, similar efficacy and toxicity in clinical studies of other bevacizumab biosimilars over bevacizumab RP while two biosimilars i.e., Pfizer’s Zirabev and Amgen’s Mvasi have been approved for unresectable, LA NSCLC and recurrent or metastatic nonsq. NSCLC

Ref: Center for Biosimilars | Image: Pharmaceutical Technology

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions